Efficacy News and Research

RSS

Olympus adds dissolvable sinus spacing and hemostat products to ENT portfolio

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, today announced the addition of a broad line of advanced, dissolvable sinus spacing and hemostat products to its already extensive ENT product portfolio. These products include spacers, foams and powders available in either plant-based or chitosan polysaccharide polymers.

From Evident Corporation - Life Sciences 6 Jan 2012

Wake Forest Baptist participates in novel brain tumor vaccine clinical trial

A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate.

6 Jan 2012

RegeneRx's RGN-259 safe, well tolerated in patients with dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. announced today that it has received the clinical study report for its recently completed Phase 2 clinical trial evaluating RGN-259 for the treatment of dry eye syndrome.

5 Jan 2012

Positive results from ProFibrix Phase II Fibrocaps clinical trial

ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general surgery resulted in a highly statistically significant reduction in mean time to hemostasis (TTH) and incidence of hemostasis at 3, 5 and 10 minutes, as compared to active control.

5 Jan 2012

Novel vaccine combinations can protect against infection by SIV

Results from a recent study show that novel vaccine combinations can provide partial protection against infection by Simian Immunodeficiency Virus (SIV) in rhesus monkeys.

5 Jan 2012

CMS acknowledges clinical improvement linked with use of Alair Bronchial Thermoplasty System

Boston Scientific Corporation announced that the Centers for Medicare and Medicaid Services (CMS), the agency that administers the Medicare program, has acknowledged the substantial clinical improvement associated with the use of the Alair Bronchial Thermoplasty System to perform bronchial thermoplasty for the management of severe asthma.

5 Jan 2012

Positive results from Alkermes ALKS 5461 phase 1/2 study on MDD

Alkermes plc today announced positive topline results from a phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

5 Jan 2012

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

5 Jan 2012

Arcion receives U.S. patent allowance for ARC-2022 to treat PHN

Arcion Therapeutics, a clinical stage biotechnology company developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent for its high strength gel formulation of topical lidocaine, ARC-2022.

5 Jan 2012

Pharmalink raises SEK 35 million to further advance Nefecon and Busulipo

Pharmalink AB, today announces it has raised SEK 35 million through a rights issue of new shares to the Company's existing shareholders, including Industrifonden.

4 Jan 2012

MTR technique indicates that COPAXONE therapy results in tissue repair in RRMS patients

Researchers utilizing an advanced magnetic resonance imaging (MRI) technology to characterize and chart the evolution of MS lesions found that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE (glatiramer acetate injection) experienced significantly increased magnetization transfer ratio.

4 Jan 2012

Antigen Express to move AE37 cancer vaccine into larger clinical trials

Generex Biotechnology Corporation today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.

4 Jan 2012

Scientists discover chemical compound that inhibits poxviruses from replicating

A team of scientists from Boston University School of Medicine (BUSM) have identified a novel compound that inhibits viruses from replicating. The findings, which are published online in the Journal of Virology, could lead to the development of highly targeted compounds to block the replication of poxviruses, such as the emerging infectious disease Monkeypox.

4 Jan 2012

$Yakult Honsha commences perifosine Phase 1/2 trial for refractory advanced colorectal cancer in Japan$

Yakult Honsha commences perifosine Phase 1/2 trial for refractory advanced colorectal cancer in Japan

Aeterna Zentaris Inc. today announced that its Japanese partner, Yakult Honsha, has initiated a Phase 1/2 trial in Japan to assess the safety and efficacy of the Company's PI3K/Akt inhibitor, perifosine, in combination with chemotherapeutic agent, capecitabine, in patients with refractory advanced colorectal cancer ("CRC").

4 Jan 2012

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange announced today the successful results of the Phase 1/2 study of its drug candidate CF102 in the treatment of hepatocellular carcinoma.

4 Jan 2012

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that tivozanib demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma.

3 Jan 2012

InSightec completes enrollment in ExAblate Neuro clinical study for Essential Tremor

InSightec Ltd, the global leader in MR guided Focused Ultrasound therapy, announced today that it has completed enrollment in the world's first feasibility study evaluating the use of MRgFUS for treatment of Essential Tremor, using ExAblate Neuro at University of Virginia, Charlottesville, Virginia.

3 Jan 2012

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDA

Cell Therapeutics, Inc. (CTI) announced today that on February 9, 2012 the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review CTI's resubmitted New Drug Application (NDA) for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy.

3 Jan 2012

DBS safe and effective for treatment-resistant depression in patients with unipolar MDD or BP

A new study shows that deep brain stimulation (DBS) is a safe and effective intervention for treatment-resistant depression in patients with either unipolar major depressive disorder (MDD) or bipolar ll disorder.

3 Jan 2012

The Scientist selects Aspect Imaging's M2 imaging platform as one of Top 10 Innovations of 2011

The Scientist today unveiled the Top 10 Innovations of 2011 and selected Aspect Imaging's M2™ compact high-performance MRI imaging system as one the winners of this award. The Scientist invited members of the life science community to submit descriptions of exciting tools that made an impact in research this year and asked a panel of expert judges to evaluate the technologies.

2 Jan 2012

Efficacy News and Research

Olympus adds dissolvable sinus spacing and hemostat products to ENT portfolio

Wake Forest Baptist participates in novel brain tumor vaccine clinical trial

RegeneRx's RGN-259 safe, well tolerated in patients with dry eye syndrome

Positive results from ProFibrix Phase II Fibrocaps clinical trial

Novel vaccine combinations can protect against infection by SIV

CMS acknowledges clinical improvement linked with use of Alair Bronchial Thermoplasty System

Positive results from Alkermes ALKS 5461 phase 1/2 study on MDD

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Arcion receives U.S. patent allowance for ARC-2022 to treat PHN

Pharmalink raises SEK 35 million to further advance Nefecon and Busulipo

MTR technique indicates that COPAXONE therapy results in tissue repair in RRMS patients

Antigen Express to move AE37 cancer vaccine into larger clinical trials

Scientists discover chemical compound that inhibits poxviruses from replicating

Yakult Honsha commences perifosine Phase 1/2 trial for refractory advanced colorectal cancer in Japan

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

InSightec completes enrollment in ExAblate Neuro clinical study for Essential Tremor

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDA

DBS safe and effective for treatment-resistant depression in patients with unipolar MDD or BP

The Scientist selects Aspect Imaging's M2 imaging platform as one of Top 10 Innovations of 2011

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News